1. Redlich, K, Schett, G, Steiner, G, et al. Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade. Arthritis Rheum 2003; 48: 3308–3319.
Google Scholar | Crossref | Medline2. Giacomelli, R, Afeltra, A, Alunno, A, et al. International consensus: what else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren’s syndrome)? the unmet needs and the clinical grey zone in autoimmune disease management. Autoimmun Rev 2017; 16: 911–924.
Google Scholar | Crossref | Medline3. Schoels, M, Aletaha, D, Smolen, JS, et al. Comparative effectiveness and safety of biological treatment options after tumour necrosis factor alpha inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Ann Rheum Dis 2012; 71: 1303–1308.
Google Scholar | Crossref | Medline | ISI4. Finckh, A, Ciurea, A, Brulhart, L, et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis 2010; 69: 387–393.
Google Scholar | Crossref | Medline5. Virkki, LM, Valleala, H, Takakubo, Y, et al. Outcomes of switching anti-TNF drugs in rheumatoid arthritis – a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN). Clin Rheumatol 2011; 30: 1447–1454.
Google Scholar | Crossref | Medline6. Chatzidionysiou, K, Askling, J, Eriksson, J, et al. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register. Ann Rheum Dis 2015; 74: 890–896.
Google Scholar | Crossref | Medline7. Bombardieri, S, Ruiz, AA, Fardellone, P, et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology 2007; 46: 1191–1199.
Google Scholar | Crossref | Medline | ISI8. Emery, P, Gottenberg, JE, Rubbert-Roth, A, et al. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor SWITCH-RA, a global, observational, comparative effectiveness study. Ann Rheum Dis 2015; 74: 979–984.
Google Scholar | Crossref | Medline9. Harrold, LR, Reed, GW, Magner, R, et al. Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry. Arthritis Res Ther 2015; 17: 256.
Google Scholar | Crossref | Medline10. Lauper, K, Nordström, DC, Pavelka, K, et al. Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biological disease modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration. Ann Rheum Dis 2018; 77: 1276–1282.
Google Scholar | Medline11. Chastek, B, Becker, LK, Chen, CI, et al. Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis. J Med Econ 2017; 20: 464–473.
Google Scholar | Crossref | Medline12. Gottenberg, JE, Brocq, O, Perdriger, A, et al. Non-TNF-targeted biological vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug. JAMA 2016; 316: 1172–1180.
Google Scholar | Crossref | Medline13. Torrente-Segarraa, V, Acosta, A, Morlac, R, et al. Estudio VARIAR: VAloración de la eficacia y seguridad a corto plazo en artritis reumatoide del uso de RItuximab comparado con Antagonistas del factor de necrosis tumoral alfa en segunda línea terapéutica en pacientes con artritis reumatoide Refractarios a un primer antagonista del factor de necrosis tumoral alfa. Reumatol Clin 2016; 12: 319–322.
Google Scholar | Medline14. Frisell, T, Dehlim, M, Giuseppe, DD, et al. Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologicals in RA: results from the nationwide Swedish register. Rheumatology 2019; 58: 1367–1377.
Google Scholar | Crossref15. Santos-Faria, D, Tavares-Costa, J, Eusébio, M, et al. Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor. Acta Reumatol Port 2019; 44: 103–113.
Google Scholar | Medline16. Buch, MH . Defining refractory rheumatoid arthritis. Ann Rheum Dis 2018; 77: 966–969.
Google Scholar | Crossref | Medline17. Finckh, A, Simard, JF, Gabay, C, et al. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 2006; 65: 746–752.
Google Scholar | Crossref | Medline | ISI18. Schiff, MH, von Kempis, J, Goldblum, R, et al. Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase. Ann Rheum Dis 2014; 73: 2174–2177.
Google Scholar | Crossref | Medline19. von Elm, E, Altman, DG, Egger, M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007; 147: 573–577.
Google Scholar | Crossref | Medline | ISI20. Kristensen, LE, Saxne, T, Geborek, P. The LUNDEX, a new index of drug efficacy in clinical practice. Arthritis Rheum 2006; 54: 600–606.
Google Scholar | Crossref | Medline21. Chatzidionysiou, K, Hetland, ML, Frisell, T, et al. Effectiveness of a second biologic after failure of a non-tumor necrosis factor inhibitor as first biologic in rheumatoid arthritis. J Rheumatol 2021; 48: 1512–1518.
Google Scholar | Crossref | Medline22. Smolen, JS, Burmester, GR, Combe, B, et al. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomized EXXELERATE study. Lancet 2016; 388: 2763–2774.
Google Scholar | Crossref | Medline23. Rémy, A, Avouac, J, Gossec, L, et al. Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis. Clin Exp Rheumatol 2011; 29: 96–103.
Google Scholar | Medline